DataSheet_2_LUBAC Suppresses IL-21-Induced Apoptosis in CD40-Activated Murine B Cells and Promotes Germinal Center B Cell Survival and the T-Dependent Antibody Response.pdf
B cell activation by Tfh cells, i.e., through CD154 engagement of CD40 and IL-21, and survival within GCs are crucial for the T-dependent Ab response. LUBAC, composed of HOIP, SHARPIN, and HOIL-1, catalyzes linear ubiquitination (Linear M1-Ub) to mediate NF-κB activation and cell survival induced by TNF receptor superfamily members, which include CD40. As shown in this study, B cells expressing the Sharpin null mutation cpdm (Sharpincpdm) could undergo proliferation, CSR, and SHM in response to immunization by a T-dependent Ag, but were defective in survival within GCs, enrichment of a mutation enhancing the BCR affinity, and production of specific Abs. Sharpincpdm B cells stimulated in vitro with CD154 displayed normal proliferation and differentiation, marginally impaired NF-κB activation and survival, but markedly exacerbated death triggered by IL-21. While activating the mitochondria-dependent apoptosis pathway in both Sharpin+/+ and Sharpincpdm B cells, IL-21 induced Sharpincpdm B cells to undergo sustained activation of caspase 9 and caspase 8 of the mitochondria-dependent and independent pathway, respectively, and ultimately caspase 3 in effecting apoptosis. These were associated with loss of the caspase 8 inhibitor cFLIP and reduction in cFLIP Linear M1-Ub, which interferes with cFLIP poly-ubiquitination at Lys48 and degradation. Finally, the viability of Sharpincpdm B cells was rescued by caspase inhibitors but virtually abrogated – together with Linear M1-Ub and cFLIP levels – by a small molecule HOIP inhibitor. Thus, LUBAC controls the cFLIP expression and inhibits the effects of caspase 8 and IL-21-activated caspase 9, thereby suppressing apoptosis of CD40 and IL-21-activated B cells and promoting GC B cell survival.
History
References
- https://doi.org//10.1038/nri2729
- https://doi.org//10.1038/nri3216
- https://doi.org//10.1016/j.immuni.2020.11.006
- https://doi.org//10.1038/ni.3460
- https://doi.org//10.1038/s41467-018-04234-4
- https://doi.org//10.1038/ncomms1769
- https://doi.org//10.1038/nrrheum.2012.58
- https://doi.org//10.1126/science.1257861
- https://doi.org//10.1126/science.1077002
- https://doi.org//10.4049/jimmunol.173.9.5361
- https://doi.org//10.1084/jem.20091777
- https://doi.org//10.1038/nri3795
- https://doi.org//10.1084/jem.20191638
- https://doi.org//10.1016/1074-7613(94)90096-5
- https://doi.org//10.1038/ni.3554
- https://doi.org//10.1016/j.immuni.2019.07.001
- https://doi.org//10.1016/j.cell.2019.03.016
- https://doi.org//10.1038/376181a0
- https://doi.org//10.1038/374163a0
- https://doi.org//10.1084/jem.186.7.1171
- https://doi.org//10.1016/j.immuni.2004.12.010
- https://doi.org//10.1016/j.celrep.2012.05.010
- https://doi.org//10.1038/nature09815
- https://doi.org//10.1038/nature09814
- https://doi.org//10.1016/j.bbrc.2018.12.164
- https://doi.org//10.1038/s42003-020-0882-8
- https://doi.org//10.1016/j.celrep.2020.01.108
- https://doi.org//10.1038/s41467-019-13603-6
- https://doi.org//10.1093/nar/gkt382
- https://doi.org//10.1093/bioinformatics/btv359
- https://doi.org//10.1038/emboj.2013.184
- https://doi.org//10.1002/eji.1830150517
- https://doi.org//10.1084/jem.176.3.679
- https://doi.org//10.1016/s1074-7613(00)80108-9
- https://doi.org//10.1002/j.1460-2075.1988.tb03038.x
- https://doi.org//10.1016/0167-5699(94)90175-9
- https://doi.org//10.1016/j.immuni.2016.09.001
- https://doi.org//10.1126/sciadv.aay2793
- https://doi.org//10.4049/jimmunol.1901170
- https://doi.org//10.3390/ijms161226232
- https://doi.org//10.1016/j.cell.2006.01.021
- https://doi.org//10.1074/jbc.RA118.005449
- https://doi.org//10.4049/jimmunol.1701526
- https://doi.org//10.1016/j.molcel.2015.03.003
- https://doi.org//10.4049/jimmunol.170.8.4111
- https://doi.org//10.4049/jimmunol.173.1.657
- https://doi.org//10.1084/jem.20091738
- https://doi.org//10.1126/science.1213368
- https://doi.org//10.1016/j.celrep.2018.10.042
- https://doi.org//10.1038/ni.2428
- https://doi.org//10.1038/ni.2418
- https://doi.org//10.1016/j.immuni.2017.06.005
- https://doi.org//10.4049/jimmunol.1701321
- https://doi.org//10.1016/j.cell.2017.11.036
- https://doi.org//10.1101/2020.06.26.117010
- https://doi.org//10.1016/j.immuni.2018.01.008
- https://doi.org//10.1038/cdd.2014.83
- https://doi.org//10.1126/sciadv.aau9433
- https://doi.org//10.1016/s0092-8674(00)81590-1
- https://doi.org//10.1084/jem.20050117
- https://doi.org//10.1038/nri1787
- https://doi.org//10.4049/jimmunol.181.8.5368
- https://doi.org//10.4049/jimmunol.182.1.207
- https://doi.org//10.4049/jimmunol.0903506
- https://doi.org//10.1371/journal.pone.0117994
- https://doi.org//10.4049/jimmunol.2000359
- https://doi.org//10.1016/j.bcp.2008.09.007
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity